The impact of HIV/HCV co‐infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort
- 9 June 2010
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 18 (7) , 506-512
- https://doi.org/10.1111/j.1365-2893.2010.01325.x
Abstract
Summary. HIV/hepatitis C virus (HCV) co‐infection places a growing burden on the HIV/AIDS care delivery system. Evidence‐based estimates of health services utilization among HIV/HCV co‐infected patients can inform efficient planning. We analyzed data from the ACTG Longitudinal Linked Randomized Trials (ALLRT) cohort to estimate resource utilization and disability among HIV/HCV co‐infected patients and compare them to rates seen in HIV mono‐infected patients. The analysis included HIV‐infected subjects enrolled in the ALLRT cohort between 2000 and 2007 who had at least one CD4 count measured and completed at least one resource utilization data collection form (N = 3143). Primary outcomes included the relative risk of hospital nights, emergency department (ED) visits, and disability days for HIV/HCV co‐infected vs HIV mono‐infected subjects. When controlling for age, sex, race, history of AIDS‐defining events, current CD4 count and current HIV RNA, the relative risk of hospitalization, ED visits, and disability days for subjects with HIV/HCV co‐infection compared to those with HIV mono‐infection were 1.8 (95% CI: 1.3–2.5), 1.7 (95% CI: 1.4–2.1), and 1.6 (95% CI: 1.3–1.9) respectively. Programs serving HIV/HCV co‐infected patients can expect approximately 70% higher rates of utilization than expected from a similar cohort of HIV mono‐infected patients.Keywords
This publication has 26 references indexed in Scilit:
- Influence of Hepatitis C Virus Infection on HIV‐1 Disease Progression and Response to Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2005
- Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy.2005
- Challenges in the Treatment of Patients Coinfected with HIV and Hepatitis C Virus: Need for Team CareClinical Infectious Diseases, 2005
- Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected PatientsA Randomized Controlled TrialJAMA, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected PatientsNew England Journal of Medicine, 2004
- AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus–Infection Health Care in the United StatesClinical Infectious Diseases, 2002
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDSQuality of Life Research, 1997
- Derivation and Properties of a Brief Health Status Assessment Instrument for Use in HIV DiseaseJAIDS Journal of Acquired Immune Deficiency Syndromes, 1995
- A Perceived Health Index for Use in Persons With Advanced HIV Disease: Derivation, Reliability, and ValidityMedical Care, 1994